CalciMedica Q2 2024 Adj EPS $(0.36) Beats $(0.53) Estimate
Portfolio Pulse from Benzinga Newsdesk
CalciMedica (NASDAQ:CALC) reported a Q2 2024 adjusted EPS of $(0.36), beating the analyst consensus estimate of $(0.53) by 32.08%.
August 12, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CalciMedica reported a Q2 2024 adjusted EPS of $(0.36), which is significantly better than the analyst consensus estimate of $(0.53). This positive earnings surprise of 32.08% is likely to have a favorable impact on the stock price in the short term.
The better-than-expected earnings per share (EPS) indicates that the company is performing better than analysts anticipated, which is generally a positive signal for investors. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100